These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 38396017)
1. Improving access to HIV care among people who inject drugs through tele-harm reduction: a qualitative analysis of perceived discrimination and stigma. Scaramutti C; Hervera B; Rivera Y; Chueng TA; Forrest DW; Suarez E; Serota DP; Alkamli H; Ciraldo K; Bartholomew TS; Tookes HE Harm Reduct J; 2024 Feb; 21(1):50. PubMed ID: 38396017 [TBL] [Abstract][Full Text] [Related]
2. Acceptability, feasibility, and pilot results of the tele-harm reduction intervention for rapid initiation of antiretrovirals among people who inject drugs. Tookes HE; Bartholomew TS; Suarez E; Ekowo E; Ginoza M; Forrest DW; Serota DP; Rodriguez A; Kolber MA; Feaster DJ; Mooss A; Boyd D; Sternberg C; Metsch LR Drug Alcohol Depend; 2021 Dec; 229(Pt A):109124. PubMed ID: 34781096 [TBL] [Abstract][Full Text] [Related]
3. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services. Bartholomew TS; Plesons M; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; Chueng TA; Ciraldo K; Brooks J; Smith JD; Barocas JA; Tookes HE Addict Sci Clin Pract; 2024 Mar; 19(1):21. PubMed ID: 38528570 [TBL] [Abstract][Full Text] [Related]
4. Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs. Tookes HE; Oxner A; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; McCollister K; Rodriguez A; Kolber MA; Chueng TA; Zayas S; McCoy B; Sutherland K; Archer C; Bartholomew TS Trials; 2023 Feb; 24(1):96. PubMed ID: 36750867 [TBL] [Abstract][Full Text] [Related]
5. Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study. Suarez E; Bartholomew TS; Plesons M; Ciraldo K; Ostrer L; Serota DP; Chueng TA; Frederick M; Onugha J; Tookes HE Ann Med; 2023 Dec; 55(1):733-743. PubMed ID: 36856571 [No Abstract] [Full Text] [Related]
6. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs. Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339 [TBL] [Abstract][Full Text] [Related]
7. Attitudes towards people living with HIV and people who inject drugs: A mixed method study of stigmas within harm reduction programs in Kazakhstan. Stringer KL; Mukherjee T; McCrimmon T; Terlikbayeva A; Primbetovac S; Darisheva M; Hunt T; Gilbert L; El-Bassel N Int J Drug Policy; 2019 Jun; 68():27-36. PubMed ID: 30981165 [TBL] [Abstract][Full Text] [Related]
8. "Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda. Kamusiime B; Beima-Sofie K; Chhun N; Nalumansi A; Nalukwago GK; Kasiita V; Twesige CC; Kansiime R; Muwonge TR; Kyambadde P; Kadama H; Mudiope P; Glick S; Lambdin B; Mujugira A; Heffron R Addict Sci Clin Pract; 2024 Feb; 19(1):13. PubMed ID: 38395940 [TBL] [Abstract][Full Text] [Related]
9. Access to HIV treatment and care for people who inject drugs in Kenya: a short report. Guise A; Rhodes T; Ndimbii J; Ayon S; Nnaji O AIDS Care; 2016 Dec; 28(12):1595-1599. PubMed ID: 27267309 [TBL] [Abstract][Full Text] [Related]
10. Pre-Exposure Prophylaxis Barriers, Facilitators and Unmet Need Among Rural People Who Inject Drugs: A Qualitative Examination of Syringe Service Program Client Perspectives. Surratt HL; Yeager HJ; Adu A; González EA; Nelson EO; Walker T Front Psychiatry; 2022; 13():905314. PubMed ID: 35706473 [TBL] [Abstract][Full Text] [Related]
11. A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts. Hassan R; Roland KB; Hernandez B; Goldman L; Evans KN; Gaul Z; Agnew-Brune C; Buchacz K; Fukuda HD J Subst Abuse Treat; 2022 Jul; 138():108722. PubMed ID: 35067399 [TBL] [Abstract][Full Text] [Related]
12. "They look at us like junkies": influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Muncan B; Walters SM; Ezell J; Ompad DC Harm Reduct J; 2020 Jul; 17(1):53. PubMed ID: 32736624 [TBL] [Abstract][Full Text] [Related]
13. Generating trust: Programmatic strategies to reach women who inject drugs with harm reduction services in Dar es Salaam, Tanzania. Zamudio-Haas S; Mahenge B; Saleem H; Mbwambo J; Lambdin BH Int J Drug Policy; 2016 Apr; 30():43-51. PubMed ID: 26880500 [TBL] [Abstract][Full Text] [Related]
14. The impact of the COVID-19 pandemic on people who inject drugs accessing harm reduction services in an rural American state. Thakarar K; Kohut M; Hutchinson R; Bell R; Loeb HE; Burris D; Fairfield KM Harm Reduct J; 2022 Jul; 19(1):80. PubMed ID: 35869523 [TBL] [Abstract][Full Text] [Related]
15. Access to and acceptability of sexual and reproductive health, harm reduction and other essential health services among people who inject drugs in Durban, South Africa. Milford C; Cavanagh T; Bosman S; Wilson M; Smit J; Zanoni B Harm Reduct J; 2024 Jun; 21(1):123. PubMed ID: 38926755 [TBL] [Abstract][Full Text] [Related]
16. Barriers and facilitators of HIV and hepatitis C care among people who inject drugs in Nairobi, Kenya: a qualitative study with peer educators. Ludwig-Barron NT; Guthrie BL; Mbogo L; Bukusi D; Sinkele W; Gitau E; Farquhar C; Monroe-Wise A Harm Reduct J; 2021 Dec; 18(1):133. PubMed ID: 34922548 [TBL] [Abstract][Full Text] [Related]
17. Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study. Kiriazova T; Go VF; Hershow RB; Hamilton EL; Sarasvita R; Bui Q; Lancaster KE; Dumchev K; Hoffman IF; Miller WC; Latkin CA Harm Reduct J; 2020 Oct; 17(1):69. PubMed ID: 32998731 [TBL] [Abstract][Full Text] [Related]
18. Factors that influence enrollment in syringe services programs in rural areas: a qualitative study among program clients in Appalachian Kentucky. Ibragimov U; Cooper KE; Batty E; Ballard AM; Fadanelli M; Gross SB; Klein EM; Lockard S; Young AM; Cooper HLF Harm Reduct J; 2021 Jun; 18(1):68. PubMed ID: 34193165 [TBL] [Abstract][Full Text] [Related]
19. Using a programmatic mapping approach to plan for HIV prevention and harm reduction interventions for people who inject drugs in three South African cities. Scheibe A; Shelly S; Lambert A; Schneider A; Basson R; Medeiros N; Padayachee K; Savva H; Hausler H Harm Reduct J; 2017 Jun; 14(1):35. PubMed ID: 28592246 [TBL] [Abstract][Full Text] [Related]
20. "We want everything in a one-stop shop": acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs. Bartholomew TS; Andraka-Cristou B; Totaram RK; Harris S; Doblecki-Lewis S; Ostrer L; Serota DP; Forrest DW; Chueng TA; Suarez E; Tookes HE Harm Reduct J; 2022 Dec; 19(1):133. PubMed ID: 36463183 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]